2017.V1版《NCCN结直肠癌诊治指南》更新解读  

Interpretation of Updated NCCN Guidelines for Colon Cancer and Rectal Cancer( Version 1. 2017)

作　　者：邵仟仟 林国乐[1] 

机构地区：[1]中国医学科学院北京协和医学院,北京协和医院基本外科,北京市100730

出　　处：《中国全科医学》2017年第6期635-638,共4页Chinese General Practice

摘　　要：本文对2017.V1版《NCCN结直肠癌诊治指南》进行了解读。与2016.V2版《NCCN结直肠癌诊治指南》相比,新版指南做出了一些能改变临床实践的更新,其中最为重要的几点包括:(1)建议服用小剂量阿司匹林作为结直肠癌(CRC)术后的二级化学预防;(2)RAS野生型转移性CRC(mCRC)的一线靶向治疗中,表皮细胞生长因子受体(EGFR)单抗仅限于左半结肠癌患者;(3)可切除肝/肺转移瘤的新辅助化疗中不推荐使用靶向药物;(4)推荐程序性死亡受体(PD-1)单抗用于MMR突变(dMMR)/MSI-H的mCRC之末线治疗。This paper interpreted NCCN Guidelines for Colon Cancer and Rectal Cancer（Version 1. 2017）. Compared with Version 2. 2016,the latest guideline made some significant updates,and the most important points included： （1） considering low - dose aspirin as the secondary chemoprevention for colorectal cancer（CRC）survivors;（2）in the first - line targeted therapy of RAS wide - type CRC（mCRC）,EGFR inhibitors（cetuximab or panitumumab）should only be offered to patients whose primary tumors originated on the left side of the colon and rectum; （ 3 ）the panel recommends against panitumumab and cetuximab in the neoadjuvant chemotherapy of resectable metastatic liver or lung neoplasms;（4）the panel recommends programmed death receptor - 1（PD - 1）inhibitors as treatment options in mCRC patients with metastatic deficient MMR（dMMR）or MSI - H in second - or third - line therapy.

关 键 词：结直肠肿瘤 NCCN指南 2017.V1版更新 

分 类 号：R735.34[医药卫生—肿瘤]